Plant Name: vernonia cinerea
Taxonomic Information:
Plant ID: NPO33276
Plant Latin Name: vernonia cinerea
Taxonomy Genus: Vernonia
Taxonomy Family: Asteraceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
1164899-2
Used in Medicines:
Unknown.
Geographical Distribution:
Brazil
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ALDH1A1; | |
| CMA1; | |
| TP53; STAT3; NFKB1; | |
| MAPT; GMNN; THPO; LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Serine protease | CMA1 | Chymase | P23946 | CHEMBL4068 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | STAT3 | Signal transducer and activator of transcription 3 | P40763 | CHEMBL4026 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | GMNN | Geminin | O75496 | CHEMBL1293278 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.417E-06 | 9.618E-02 | CYP2C19, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.940E-05 | 1.480E-01 | CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 6.769E-05 | 2.105E-01 | STAT3, TP53 |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 8.782E-05 | 2.111E-01 | STAT3, TP53 |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 1.031E-04 | 2.111E-01 | MAPT, STAT3, TP53 |
| BP | GO:0008152; metabolic process | GO:0042445; hormone metabolic process | 1.348E-04 | 2.111E-01 | ALDH1A1, CMA1, CYP3A4 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 1.106E-04 | 2.111E-01 | MAPT, TP53 |
| MF | GO:0005488; binding | GO:0003682; chromatin binding | 1.277E-04 | 2.111E-01 | GMNN, NFKB1, STAT3, TP53 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.638E-04 | 2.229E-01 | CYP2C19, CYP3A4 |
| MF | GO:0005488; binding | GO:0008134; transcription factor binding | 2.396E-04 | 2.943E-01 | GMNN, NFKB1, STAT3, TP53 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.880E-04 | 2.986E-01 | CYP2C19, CYP3A4 |
| CC | GO:0032991; macromolecular complex | GO:0090575; RNA polymerase II transcription factor complex | 2.412E-03 | 4.689E-01 | STAT3, TP53 |
| CC | GO:0032991; macromolecular complex | GO:0033256; I-kappaB/NF-kappaB complex | 3.980E-03 | 5.128E-01 | NFKB1 |
| CC | GO:0043226; organelle | GO:0016604; nuclear body | 6.644E-03 | 5.762E-01 | LMNA, MAPT, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 5.558E-06 | 4.946E-04 | STAT3, TP53, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 5.316E-05 | 1.072E-03 | LMNA, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 4.562E-05 | 1.072E-03 | STAT3, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 4.876E-05 | 1.072E-03 | STAT3, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 6.024E-05 | 1.072E-03 | STAT3, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 1.578E-04 | 1.833E-03 | STAT3, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.648E-04 | 1.833E-03 | STAT3, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 3.133E-04 | 3.099E-03 | MAPT, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 4.317E-04 | 3.704E-03 | STAT3, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.108E-04 | 1.643E-03 | CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.897E-04 | 3.704E-03 | STAT3, TP53, NFKB1 |
| 09160 Human Diseases | 09162 Immune diseases | hsa05321 | Inflammatory bowel disease (IBD) | 5.613E-04 | 3.704E-03 | STAT3, NFKB1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 5.613E-04 | 3.704E-03 | ALDH1A1, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 6.883E-04 | 3.704E-03 | STAT3, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.138E-03 | 4.731E-03 | STAT3, TP53, NFKB1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 6.323E-04 | 3.704E-03 | CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 7.075E-04 | 3.704E-03 | TP53, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04920 | Adipocytokine signaling pathway | 6.507E-04 | 3.704E-03 | STAT3, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.049E-03 | 4.669E-03 | TP53, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.348E-03 | 5.197E-03 | STAT3, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 9.802E-04 | 4.591E-03 | TP53, NFKB1 |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 1.169E-03 | 4.731E-03 | TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.917E-04 | 4.409E-03 | CYP3A4, CYP2C19 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.402E-03 | 5.197E-03 | STAT3, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 1.568E-03 | 5.581E-03 | STAT3, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 1.833E-03 | 6.024E-03 | STAT3, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 1.895E-03 | 6.024E-03 | TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 3.255E-03 | 9.989E-03 | THPO, STAT3 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.895E-03 | 6.024E-03 | TP53, NFKB1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
